ADTX Aditxt, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ADTX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$0.62
52W High
$4463.5
52W Low
$0.58
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$1.1M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
95%
Analysis Accuracy
ADTX exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of an Altman Z-Score, which raises significant bankruptcy risk. The company is unprofitable with a negative ROA of -61.70%, a gross margin of 0.00%, and a staggering -419,870.30% operating margin. Revenue has collapsed by 89.10% YoY, and the stock has declined 100% over the past five years. Despite a low current price of $0.62, the valuation metrics—such as a Price/Sales of 184.38 and negative forward P/E—suggest extreme overvaluation relative to fundamentals, likely driven by speculative momentum rather than earnings potential.
Key Strengths
Recent quarterly EPS growth of +6.9% Q/Q suggests possible short-term earnings stabilization
Insider activity includes a small number of sales, but no buys, indicating cautious sentiment
Trading volume remains active, suggesting market interest despite fundamentals
Low price point ($0.62) may attract speculative traders seeking high-risk, high-reward opportunities
Peer comparison shows some biotech stocks with similar market caps also experiencing extreme volatility
Key Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and poor operational efficiency
Negative ROA (-61.70%) and operating margin (-419,870.30%) signal deep unprofitability
Current ratio and quick ratio of 0.02 indicate extreme liquidity risk and inability to meet short-term obligations
Revenue has declined 89.10% YoY, with no signs of recovery in the near term
No analyst coverage or target price, indicating lack of institutional interest and high uncertainty
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
7
Weak
10
10
10
5
0
AI Verdict
High Risk - Distressed
Key drivers: Piotroski F-Score of 1/9, Negative operating and ROA metrics, 90%+ revenue decline, Extreme liquidity risk, No analyst coverage
Confidence
95%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 184.38 is astronomically high for a loss-making company
- No Graham Number or intrinsic value available
- Forward P/E of -0.05 indicates no earnings expectations
- Current price is not supported by any fundamental valuation metric
Future
10/100
Ref Growth rates
Positives
- Q/Q EPS growth of +6.9% may indicate a potential bottoming out
Watchpoints
- Revenue growth is -89.10% YoY
- No forward earnings guidance or positive growth trends
- No analyst estimates or target prices to support future performance
Past
10/100
Ref Historical trends
Positives
- One quarter beat estimate (2023-04-17) with a +310.8% surprise
Watchpoints
- Three out of four quarters missed estimates by large margins
- Average earnings surprise of -96.38%
- Historical losses are increasing in magnitude
Health
5/100
Ref Altman Z-Score, Piotroski F-Score
Positives
No standout positives identified.
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial weakness
- Current and quick ratios of 0.02 signal extreme liquidity risk
- No available Altman Z-Score, but low ratios and negative ROA suggest distress
- Negative ROA and operating margin indicate poor capital efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Company is unprofitable and likely cannot sustain dividends
- Dividend strength is 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.62
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADTX and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADTX
Aditxt, Inc.
Primary
|
-100.0% | -100.0% | -100.0% | -99.5% | -15.5% | -5.2% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
ACON
Aclarion, Inc.
Peer
|
-100.0% | -100.0% | -98.0% | -64.7% | -38.3% | -6.2% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -99.9% | -94.2% | -92.4% | -40.2% | +18.1% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.05
PEG Ratio
N/A
P/B Ratio
-0.0
P/S Ratio
184.38
EV/Revenue
795.59
EV/EBITDA
-0.23
Market Cap
$1.1M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-419870.0%
Gross Margin
N/A
ROE
N/A
ROA
-61.7%
Growth
Revenue and earnings growth rates
Revenue Growth
-89.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.02
Weak
Quick Ratio
0.02
Poor
Cash/Share
$0.29
Quarterly Earnings History
EPS performance vs analyst estimates
2023-11-14
$-55109835.47
-511.1% surprise
2023-05-15
$-59211715.78
-48.9% surprise
2023-04-17
$141023323.09
+310.8% surprise
2022-11-14
$-238202856.63
-136.3% surprise
Healthcare Sector Comparison
Comparing ADTX against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Revenue Growth
-89.1%
This Stock
vs
61.93%
Sector Avg
-243.9%
(Slower)
Current Ratio
0.02
This Stock
vs
3.47
Sector Avg
-99.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADTX
Aditxt, Inc.
|
BEARISH | $1.1M | - | -% | -% | $0.62 | |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | |
|
ACON
Aclarion, Inc.
|
BEARISH | $2.72M | - | -97.7% | -% | $2.58 | |
|
AKAN
Akanda Corp.
|
BEARISH | $3.03M | 0.01 | -60.9% | -266.3% | $1.5 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-17 | BRADY BRIAN MICHAEL | Director | Sale | 1 | $2 |
| 2025-11-25 | PANKOVCIN CORINNE D | Officer | Sale | 1 | $3 |
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning ADTX from our newsroom.
Newest → oldest
No matching news yet.